N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in Parkinson's disease models - PubMed
5 hours ago
- #N-acetyl-l-leucine
- #Parkinson's disease
- #synaptic function
- N-acetyl-l-leucine (NALL) reduces phosphorylated α-synuclein (pS129-syn) levels in Parkinson's disease (PD) models.
- NALL upregulates lysosomal, mitochondrial, and synaptic proteins without causing cytotoxicity.
- The reduction of pS129-syn by NALL depends on the serine protease HTRA1.
- NALL increases wild-type parkin expression, improving synaptic function in dopaminergic neurons.
- In LRRK2R1441C knockin mice, NALL decreases pS129-syn, elevates parkin levels, and improves motor learning deficits.
- NALL shows therapeutic potential for PD by targeting α-synuclein pathology and synaptic dysfunction.